Mainstay is a medical device company focused on commercializing an innovative implantable Restorative Neurostimulation system, ReActiv8®, for people with disabling Chronic Low Back Pain (CLBP). The Company is headquartered in Dublin, Ireland. It has subsidiaries operating in Ireland, the United States, Australia, Germany and the Netherlands.
Mainstay Medical does not regularly monitor, screen, or check this account. Any comments, questions, or posts left by visitors, will not be reviewed timely or receive a response. If you have any questions about Mainstay or the ReActiv8 product, please visit www.mainstaymedical.com.
Location: Ireland
Employees: 51-200
Total raised: $125M
Founded date: 2008
Investors 1
| Date | Name | Website |
| 29.01.2022 | IPF Partne... | ipfpartner... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 27.02.2024 | - | $125M | - |
Mentions in press and media 13
| Date | Title | Description | Source |
| 20.03.2024 | Mainstay Medical Announces Publication of the First Neurom... | Groundbreaking ReActiv8-B study supports the long-term efficacy, safety and durability of ReActiv8® ... | fh-partner... |
| 13.03.2024 | Mainstay Medical Announces Publication of Clinical Results... | Efficacy of ReActiv8® Restorative Neurostimulation™ shows no statistically or clinically meaningful ... | fh-partner... |
| 28.02.2024 | Mainstay Medical Secures $125M Funding for Revolutionary Bac... | Dublin-based Mainstay Medical Holdings recently announced a major equity financing deal, raising a w... | parsers.vc... |
| 27.02.2024 | Dublin-based Mainstay Medical Holdings raises USD 125 millio... | Dublin, Ireland-based medical device company, Mainstay Medical Holdings raised an equity financing i... | vcbay.news... |
| 27.02.2024 | Mainstay Medical Announces US$125M Equity Financing Transact... | Mainstay Medical Holdings, a Dublin, Ireland-based medical device company, announced an equity finan... | finsmes.co... |
| 26.02.2024 | Mainstay Medical Announces US$125 Million Equity Financing... | Funding to accelerate commercial growth and expand clinical and health economic evidence for ReActiv... | fh-partner... |
| 13.02.2024 | Mainstay Medical Announces Receipt of FDA Approval for MRI... | U.S. patients implanted with ReActiv8 now eligible for full-body MRI scans Mainstay Medical Holdi... | fh-partner... |
| 29.08.2023 | Mainstay Medical Announces Completion of Enrollment of RES... | Randomized controlled clinical trial expected to validate effectiveness of ReActiv8® Restorative Neu... | fh-partner... |
| 30.09.2022 | Mainstay Medical Announces Publication of Three-Year Patie... | Mainstay Medical Holdings plc today announced the publication of the three-year patient outcomes d... | fh-partner... |
| 23.09.2022 | United Kingdom National Institute for Health and Care Exce... | Mainstay Medical Holdings plc announced today that the National Institute for Health and Care Excell... | fh-partner... |
Show more